Launched a decade ago, the US Food and Drug Administration's Critical Path Initiative has helped catalyse the formation of many consortia focused on drug development challenges.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
E.Z. is an employee and shareholder of Sanofi. J.W., M.B. and D.G. declare no competing interests.
Rights and permissions
About this article
Cite this article
Woodcock, J., Brumfield, M., Gill, D. et al. The driving role of consortia on the critical path to innovative therapies. Nat Rev Drug Discov 13, 781 (2014). https://doi.org/10.1038/nrd4462
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd4462
